Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis

  • Holly Kimko
  • Ekaterina Gibiansky
  • Leonid Gibiansky
  • H. Lynn Starr
  • Joris Berwaerts
  • Joseph Massarella
  • Frank Wiegand
Original Paper


Placebo and pharmacodynamic (PD) models were developed which link temporal measures of efficacy in children with attention deficit hyperactivity disorder (ADHD) and methylphenidate (MPH) plasma concentrations from adults. These models can be used to predict daily pediatric clinical measure profiles following administration of different MPH formulations in children without conducting pediatric pharmacokinetic (PK) or PD studies by using more easily obtained adult PK data. Mean PK data from various extended-release MPH formulations studied in adults and mean PD data from nine pediatric efficacy studies were obtained from the literature. The individual time-course of the clinical measures from three pediatric trials were also analyzed after being combined with the meta-analysis data. The clinical measure profiles following placebo administration were described by indirect response models with time-varying elimination rates. MPH pharmacodynamic effect was described by Emax models, which included time-dependent tolerance. Internal and external evaluations using a visual predictive check technique confirmed the prediction capability of the models. This modeling exercise demonstrated that time courses of MPH concentrations in adults with different drug release patterns can be used to predict time courses of clinical efficacy parameters in pediatrics by employing the models developed by meta-analysis.


Methylphenidate pharmacodynamics Attention deficit hyperactivity disorder Meta-analysis Population modeling Placebo model 



Conflict of interest disclosures

Ekaterina Gibiansky and Leonid Gibiansky are paid consultants of Johnson & Johnson. All the other authors are employees of Johnson & Johnson.

Supplementary material

10928_2011_9238_MOESM1_ESM.doc (148 kb)
Supplementary material 1 (DOC 147 kb)


  1. 1.
    Samtani MN (2010) Simple pharmacometric tools for oral anti-diabetic drug development: competitive landscape for oral non-insulin therapies in Type 2 diabetes. Biopharm Drug Dispos 31:162–177PubMedGoogle Scholar
  2. 2.
    Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T (2010) Alzheimer’s Disease Working Group. Disease progression meta-analysis model in Alzheimer’s disease. Alzheimers Dement 6:39–53PubMedCrossRefGoogle Scholar
  3. 3.
    Luu KT, Raber SR, Nickens DJ, Vicini P (2010) A model-based meta-analysis of the effect of Latanoprost chronotherapy on the circadian intraocular pressure of patients with glaucoma or ocular hypertension. Clin Pharmacol Ther 87(4):421–425PubMedCrossRefGoogle Scholar
  4. 4.
    Mandema JW, Cox E, Alderman J (2005) Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain–results of a model-based meta-analysis that accounts for encapsulation. Cephalalgia 25:715–725PubMedCrossRefGoogle Scholar
  5. 5.
    Mandema JW, Hermann D, Wang W, Sheiner T, Milad M, Bakker-Arkema R, Hartman D (2005) Model-based development of gemcabene, a new lipid-altering agent. AAPS J 7(3):E513–E522PubMedCrossRefGoogle Scholar
  6. 6.
    Ahn JE, French JL (2010) Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation. J Pharmacokinet Pharmacodyn 37:179–201PubMedCrossRefGoogle Scholar
  7. 7.
    Kimko HC, Cross JT, Abernethy CD (1999) Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 37(6):457–470PubMedCrossRefGoogle Scholar
  8. 8.
    Wigal SB, Gupta S, Heverin E, Starr HL (2011) Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 21(3):255–263PubMedCrossRefGoogle Scholar
  9. 9.
    Swanson JM (2002) School-Based assessments and interventions for ADD students. KC Publishing, IrvineGoogle Scholar
  10. 10.
    Swanson J, Gupta S, Guinta D, Flynn D, Agler D, Lerner M, Williams L, Shoulson I, Wigal S (1999) Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther 66(3):295–305PubMedCrossRefGoogle Scholar
  11. 11.
    Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ (2004) COMACS Study Group. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 113(3 Pt 1):e206–e216PubMedCrossRefGoogle Scholar
  12. 12.
    Brams M, Muniz R, Childress A, Giblin J, Mao A, Turnbow J, Borrello M, McCague K, Lopez FA, Silva R (2008) A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect. CNS Drugs 22(8):693–704PubMedCrossRefGoogle Scholar
  13. 13.
    Muniz R, Brams M, Mao A, McCague K, Pestreich L, Silva R (2008) Efficacy and safety of extended-release dexmethylphenidate compared with d, l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study. J Child Adolesc Psychopharmacol 18(3):248–256PubMedCrossRefGoogle Scholar
  14. 14.
    Lopez F, Silva R, Pestreich L, Muniz R (2003) Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatr Drugs 5(8):545–555PubMedCrossRefGoogle Scholar
  15. 15.
    Silva R, Muniz R, McCague K, Childress A, Brams M, Mao A (2008) Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and d, l-Methylphenidate and Placebo in a laboratory classroom setting. Psychopharmacol Bull 41(1):19–33PubMedGoogle Scholar
  16. 16.
    Silva RR, Muniz R, Pestreich L, Childress A, Brams M, Lopez FA, Wang J (2006) Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 16(3):239–251PubMedCrossRefGoogle Scholar
  17. 17.
    Meeting of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology April 13, 2010, BRIEFING INFORMATION p 32 (Accessed June 20, 2011)
  18. 18.
    Tuerck D, Appel-Dingemanse S, Maboudian M, Pommier F, Wang Y, Sedek G (2007) Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. J Clin Pharmacol 47(1):64–69PubMedCrossRefGoogle Scholar
  19. 19.
    Gonzalez MA, Pentikis HS, Anderl N, Benedid MF, DeCory HH, Hirshey Dirksen SJ, Hatch SJ (2002) Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 40(4):175–184PubMedGoogle Scholar
  20. 20.
    Handen BL, Janosky J, McAuliffe S, Breaux AM, Feldman H (1994) Prediction of response to methylphenidate among children with ADHD and mental retardation. J Am Acad Child Adolesc Psychiatry 33(8):1185–1193PubMedCrossRefGoogle Scholar
  21. 21.
    Hermens DF, Cooper NJ, Kohn M, Clarke S, Gordon E (2005) Predicting stimulant medication response in ADHD: evidence from an integrated profile of neuropsychological, psychophysiological and clinical factors. J Integr Neurosci 4(1):107–121PubMedCrossRefGoogle Scholar
  22. 22.
    Sonuga-Barke EJS, Swanson JM, Coghill D, DeCory HH, Hatch SJ (2004) Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: Preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 4:28PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Holly Kimko
    • 1
  • Ekaterina Gibiansky
    • 2
  • Leonid Gibiansky
    • 2
  • H. Lynn Starr
    • 3
  • Joris Berwaerts
    • 4
  • Joseph Massarella
    • 5
  • Frank Wiegand
    • 6
  1. 1.Advanced Modeling & SimulationJanssen Research & Development, LLCRaritanUSA
  2. 2.QuantPharm, LLCNorth PotomacUSA
  3. 3.CNS Medical AffairsJanssen Scientific Affairs, LLCTitusvilleUSA
  4. 4.Neuroscience Therapeutic AreaJanssen Research & Development, LLCTitusvilleUSA
  5. 5.Clinical PharmacologyJanssen Research & Development, LLCRaritanUSA
  6. 6.Neurosciences Global Medical AffairsJanssen Global Services, LLCRaritanUSA

Personalised recommendations